Giovanni D'Arena1, Candida Vitale2,3, Omar Perbellini4, Marta Coscia2,3, Francesco La Rocca5, Vitalba Ruggieri5, Carlo Visco4, Nicola Matteo Dario Di Minno6, Idanna Innocenti7, Vincenzo Pizza8, Silvia Deaglio9, Giovanni Di Minno6, Aldo Giudice10, Gioacchino Calapai11, Pellegrino Musto12, Luca Laurenti7, Eugenio Luigi Iorio13. 1. Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy. 2. Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy. 3. Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy. 4. Hematology Unit, "S. Bortolo" Hospital, Vicenza, Italy. 5. Laboratory of Pre-Clinical and Translational Research, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy. 6. Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, "Federico II" University, Napoli, Italy. 7. Hematology Department, Catholic University of "Sacred Hearth", Roma, Italy. 8. Neurophisiopathology Unit, "S. Luca" Hospital, Vallo della Lucania, Italy. 9. Department of Medical Sciences, University of Torino, Torino, Italy. 10. Epidemiology Unit, Istituto Nazionale dei Tumori, "Fondazione G. Pascale", IRCCS, Napoli, Italy. 11. Department of Biomedical and Dental Sciences and Morphological and Functional Sciences, University of Messina, Messina, Italy. 12. Scientific Direction, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy. 13. International Observatory of Oxidative Stress, Salerno, Italy.
Abstract
OBJECTIVE: To evaluate the prognostic significance of oxidative stress (OS) and antioxidant defence status measurement in patients with chronic lymphocytic leukaemia (CLL). METHODS: d-ROMs test and BAP test were evaluated at diagnosis of 165 patients with CLL and correlated with clinical-biological features and prognosis. RESULTS: An increased oxidative damage (d-ROMs test) and a reduced antioxidant potential (BAP test) were found in CLL patients than normal controls (P<.0001). CLL patients with higher d-ROMs values had higher number of circulating white blood cells and lymphocytes, and higher values of β2 -microglobulin. Higher d-ROMs values were found in female (P=.0003), in patients with unmutated IgVH (P=.04), unfavourable cytogenetics (P=.002) and more advanced clinical stage (P=.002). Higher BAP test values were found in patients expressing CD49d (P=.01) and with more advanced clinical stage (P=.004). At a median follow-up of 48 months, CLL patients with d-ROMs ≥418 CARR U were found to have a shorter time to first treatment (TFT) (P=.0002), and a reduced survival (P=.006) than others. CLL patients with BAP test values ≥2155 μmol/L had a shorter TFT (P=.008) and a shorter survival (P=.003). CONCLUSIONS: OS can affect CLL patients by concomitantly increasing reactive oxygen metabolites production and decreasing antioxidant defences.
OBJECTIVE: To evaluate the prognostic significance of oxidative stress (OS) and antioxidant defence status measurement in patients with chronic lymphocytic leukaemia (CLL). METHODS: d-ROMs test and BAP test were evaluated at diagnosis of 165 patients with CLL and correlated with clinical-biological features and prognosis. RESULTS: An increased oxidative damage (d-ROMs test) and a reduced antioxidant potential (BAP test) were found in CLLpatients than normal controls (P<.0001). CLLpatients with higher d-ROMs values had higher number of circulating white blood cells and lymphocytes, and higher values of β2 -microglobulin. Higher d-ROMs values were found in female (P=.0003), in patients with unmutated IgVH (P=.04), unfavourable cytogenetics (P=.002) and more advanced clinical stage (P=.002). Higher BAP test values were found in patients expressing CD49d (P=.01) and with more advanced clinical stage (P=.004). At a median follow-up of 48 months, CLLpatients with d-ROMs ≥418 CARR U were found to have a shorter time to first treatment (TFT) (P=.0002), and a reduced survival (P=.006) than others. CLLpatients with BAP test values ≥2155 μmol/L had a shorter TFT (P=.008) and a shorter survival (P=.003). CONCLUSIONS: OS can affect CLLpatients by concomitantly increasing reactive oxygen metabolites production and decreasing antioxidant defences.
Authors: Marta Masternak; Bartosz Puła; Joanna Knap; Anna Waszczuk-Gajda; Joanna Drozd-Sokołowska; Kamil Wdowiak; Sebastian Grosicki; Izabela Kozłowska; Marta Kaźmierczak; Anna Łabędź; Łukasz Szukalski; Kamil Wiśniewski; Edyta Subocz; Janusz Hałka; Agnieszka Szymczyk; Marek Hus; Krzysztof Jamroziak; Krzysztof Giannopoulos Journal: Cancer Manag Res Date: 2020-10-12 Impact factor: 3.989
Authors: Anna Smukowska-Gorynia; Piotr Rzymski; Justyna Marcinkowska; Barbara Poniedziałek; Anna Komosa; Artur Cieslewicz; Sylwia Slawek-Szmyt; Magdalena Janus; Aleksander Araszkiewicz; Stanislaw Jankiewicz; Iga Tomaszewska-Krajniak; Tatiana Mularek-Kubzdela Journal: Oxid Med Cell Longev Date: 2019-12-18 Impact factor: 6.543